ORAL VINORELBINE PLUS CISPLATIN VERSUS PEMETREXED PLUS CISPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER: A COST MINIMIZATION ANALYSIS IN TWELVE EUROPEAN COUNTRIES

被引：0
|
作者：
Bucher, D. [1 ]
Grossi, F. [2 ]
机构：
[1] Pierre Fabre, Boulogne Billancourt, France
[2] Natl Inst Canc Res, Genoa, Italy
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1112
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN96
引用
收藏
页码：A446 / A446
页数：1
相关论文
共 50 条
  • [1] Oral vinorelbine plus cisplatin versus pemetrexed plus cisplatin as first-line treatment of advanced non-squamous non-small-cell lung cancer: cost minimization analysis in 12 European countries
    Grossi, Francesco
    Bennouna, Jaafar
    Havel, Libor
    Hochmair, Maximillian
    Almodovar, Teresa
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (09) : 1577 - 1584
  • [2] An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia
    Chang, John Wen-Cheng
    Thongprasert, Sumitra
    Wright, Elaine
    Tsang, Kenneth
    Kim, Heung Tae
    Ahn, Myung-Ju
    Kim, Joo-Hang
    Kang, Jin Hyoung
    Kim, Sang-We
    Walzer, Stefan
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 : 13 - 21
  • [3] Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer
    Farhat, Fadi S.
    Ghosn, Marwan G.
    Kattan, Joseph G.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (02) : 235 - 242
  • [4] Oral vinorelbine plus cisplatin followed by maintenance oral vinorelbine as first-line treatment for advanced non-small cell lung cancer
    Fadi S. Farhat
    Marwan G. Ghosn
    Joseph G. Kattan
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 235 - 242
  • [5] EFFICIENCY OF CISPLATIN, PEMETREXED, AND BEVACIZUMAB AS FIRST-LINE TREATMENT FOR JAPANESE ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER PATIENTS
    Shiraishi, Yoshimasa
    Hirai, Humihiko
    Yamaguchi, Masafumi
    Morodomi, Yosuke
    Toyozawa, Ryo
    Inamasu, Eiko
    Kojo, Miyako
    Toyokawa, Gouji
    Takenaka, Tomoyoshi
    Seto, Takashi
    Takenoyama, Mitsuhiro
    Ichinose, Yukito
    JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) : S488 - S488
  • [6] First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naive patients
    Leon, Luis
    Vazquez, Sergio
    Manuel Gracia, Jose
    Casal, Joaquin
    Lazaro, Martin
    Luis Firvida, Jose
    Amenedo, Margarita
    Santome, Lucia
    Macia, Sonia
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (10) : 1389 - 1396
  • [7] RETROSPECTIVE STUDY OF COMBINATION CHEMOTHERAPY WITH CISPLATIN PLUS PEMETREXED AS FIRST LINE THERAPY FOR ADVANCED NON-SMALL CELL NON-SQUAMOUS LUNG CANCER
    Inui, Toshiya
    Yokoyama, Takuma
    Takata, Saori
    Hirata, Aya
    Nishizawa, Tomotaka
    Hirukawa, Ichiro
    Wada, Hiroo
    Ishii, Haruyuki
    Takizawa, Hajime
    Goto, Hajime
    RESPIROLOGY, 2013, 18 : 149 - 149
  • [8] Cost-Utility Analysis of First-Line Pemetrexed Plus Cisplatin in Non-Small Cell Lung Cancer in Thailand
    Permsuwan, Unchalee
    Thongprasert, Sumitra
    Sirichanchuen, Buntitabhon
    VALUE IN HEALTH REGIONAL ISSUES, 2020, 21 : 9 - 16
  • [9] PHARMACOGENETIC STUDY OF JAPANESE PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER TREATED WITH PEMETREXED PLUS CISPLATIN
    Imai, Hisao
    Takahashi, Toshiaki
    Serizawa, Masakuni
    Mori, Keita
    Ono, Akira
    Akamatsu, Hiroaki
    Taira, Tetsuhiko
    Nakamura, Yukiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Murakami, Haruyasu
    Koh, Yasuhiro
    Endo, Masahiro
    Nakajima, Takashi
    Yamamoto, Nobuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1077 - S1077
  • [10] COST COMPARISON OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE VERSUS PEMETREXED AND CISPLATIN THERAPY IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL CANCER IN GERMANY - AN UPDATED ANALYSIS
    Bischoff, H. G.
    Hermes, A.
    Heigener, D. F.
    Cesaro-Tadic, S.
    Walzer, S.
    Nuijten, M.
    VALUE IN HEALTH, 2010, 13 (03) : A39 - A39
12345